The company intends to sell 5 million shares of common stock, with underwriters holding a 30-day option for an additional 750,000 units to cover over-allotments. Nuvectis expects to generate $100 million in gross proceeds from the transaction. Management plans to funnel these funds into pipeline development, personnel expansion, and general capital expenditures.
In section Market Quotes
Nuvectis Pharma Shares Plunge Following $100 Million Offering
Investors sent Nuvectis Pharma shares tumbling 34% on Tuesday to $18.91, a sharp reversal after the company priced its latest public offering at $20 per share. The move comes just one day after the biopharmaceutical firm hit a 52-week high of $29.28, effectively cooling a rally that had doubled the stock's value this year.
Nuvectis first signaled its intent to initiate the offering after Monday's market close, though it withheld specific pricing and volume details until Tuesday. The market's reaction reflects a cautious recalibration following the company's recent surge, as shareholders weigh the impact of potential dilution against the firm's long-term development goals.
Comments (0)
No comments yet. Be the first!